Harrow (HROW) to Release Quarterly Earnings on Thursday

Harrow (NASDAQ:HROW) is projected to release its Q4 2025 results before the market opens on Thursday, March 26th. Analysts expect Harrow to post earnings of $0.40 per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, March 3, 2026 at 8:00 AM ET.

Harrow Trading Down 2.1%

NASDAQ HROW opened at $34.48 on Thursday. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20. The firm has a market cap of $1.28 billion, a price-to-earnings ratio of -202.81 and a beta of 0.05. The firm has a 50 day simple moving average of $45.14 and a 200-day simple moving average of $43.55. Harrow has a one year low of $20.85 and a one year high of $54.85.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company increased its position in shares of Harrow by 2.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock valued at $505,000 after purchasing an additional 341 shares during the last quarter. Captrust Financial Advisors lifted its position in shares of Harrow by 0.5% during the 4th quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock worth $3,428,000 after purchasing an additional 376 shares during the last quarter. Alliancebernstein L.P. lifted its position in shares of Harrow by 1.7% during the 3rd quarter. Alliancebernstein L.P. now owns 29,520 shares of the company’s stock worth $1,422,000 after purchasing an additional 500 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Harrow during the fourth quarter worth $26,000. Finally, Cetera Investment Advisers increased its holdings in Harrow by 2.6% in the fourth quarter. Cetera Investment Advisers now owns 23,256 shares of the company’s stock valued at $1,140,000 after buying an additional 597 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Nomura lowered shares of Harrow to a “neutral” rating in a report on Wednesday. Zacks Research lowered Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 3rd. William Blair reiterated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. HC Wainwright lifted their target price on Harrow from $69.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Harrow has a consensus rating of “Moderate Buy” and an average price target of $71.14.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.